Mankind Pharma Limited (NSE:MANKIND)

Mankind Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	5,593	4,074	3,820	3,048	3,025	1,672
Short-Term Investments	29,393	4,266	8,160	1,413	1,023	5,311
Trading Asset Securities	-	16,908	22,581	10,755	8,745	13,062
Cash & Short-Term Investments	34,986	25,248	34,561	15,216	12,793	20,045
Cash Growth	-25.98%	-26.95%	127.13%	18.94%	-36.18%	84.76%
Accounts Receivable	19,006	15,383	8,483	5,764	3,882	3,306
Other Receivables	-	461.3	438.2	321.02	347.23	698.18
Receivables	19,042	15,884	8,950	6,102	4,241	4,188
Inventory	19,718	20,937	15,535	14,985	17,602	11,835
Prepaid Expenses	-	611.2	603.9	331.6	1,360	369.43
Other Current Assets	7,376	7,202	6,033	6,645	8,072	2,628
Total Current Assets	81,121	69,883	65,682	43,279	44,068	39,066
Property, Plant & Equipment	33,198	32,140	31,387	30,170	23,896	19,917
Long-Term Investments	4,644	4,848	3,111	3,578	2,404	2,097
Goodwill	64,926	64,926	200.2	200.23	204.42	204.42
Other Intangible Assets	98,446	101,236	16,630	17,584	18,742	187.62
Long-Term Deferred Tax Assets	1,305	1,079	803.9	297.77	392.86	490.11
Other Long-Term Assets	4,491	3,484	1,818	2,046	1,770	1,763
Total Assets	288,133	277,595	119,633	97,154	91,477	63,726
Accounts Payable	13,014	11,334	7,771	10,082	10,764	6,670
Accrued Expenses	-	7,812	5,487	1,710	2,598	1,287
Short-Term Debt	-	26,957	1,515	1,150	8,052	1,973
Current Portion of Long-Term Debt	41,391	2,611	196.9	244.68	242.47	185.02
Current Portion of Leases	212.1	143.9	34.2	25.57	20.57	16.22
Current Income Taxes Payable	275.7	180.8	83.8	462.56	150.9	110.85
Current Unearned Revenue	-	1,940	1,859	1,662	1,394	148.34
Other Current Liabilities	16,083	5,656	4,251	3,294	3,013	3,144
Total Current Liabilities	70,976	56,636	21,197	18,631	26,235	13,534
Long-Term Debt	41,658	55,262	248.7	231.47	491.94	576.7
Long-Term Leases	425.1	140.3	77.1	51.78	29.9	45.11
Long-Term Unearned Revenue	203.1	200	229.6	254.95	201.54	78.87
Pension & Post-Retirement Benefits	1,578	1,551	1,231	978.89	800.04	722.44
Long-Term Deferred Tax Liabilities	17,987	18,125	890.7	773.12	556.21	130.32
Other Long-Term Liabilities	18.9	-	-	-	-	10
Total Liabilities	132,846	131,914	23,875	20,922	28,314	15,097
Common Stock	412.8	412.6	400.6	400.59	400.59	400.59
Additional Paid-In Capital	-	30,075	421.2	421.17	421.17	421.17
Retained Earnings	-	121,451	101,566	82,499	69,729	55,413
Comprehensive Income & Other	152,447	-8,615	-8,757	-8,969	-8,999	-9,014
Total Common Equity	152,860	143,324	93,631	74,352	61,552	47,220
Minority Interest	2,427	2,358	2,127	1,881	1,611	1,409
Shareholders' Equity	155,287	145,682	95,758	76,233	63,163	48,629
Total Liabilities & Equity	288,133	277,595	119,633	97,154	91,477	63,726
Total Debt	83,687	85,115	2,072	1,704	8,836	2,796
Net Cash (Debt)	-48,701	-59,867	32,489	13,512	3,957	17,249
Net Cash Growth	-	-	140.44%	241.51%	-77.06%	81.29%
Net Cash Per Share	-118.58	-147.93	80.99	33.73	9.88	43.06
Filing Date Shares Outstanding	412.84	412.58	400.64	400.59	400.59	400.59
Total Common Shares Outstanding	412.84	412.58	400.59	400.59	400.59	400.59
Working Capital	10,146	13,247	44,485	24,647	17,834	25,532
Book Value Per Share	370.26	347.39	233.73	185.61	153.65	117.88
Tangible Book Value	-10,512	-22,838	76,800	56,568	42,606	46,828
Tangible Book Value Per Share	-25.46	-55.35	191.72	141.21	106.36	116.90
Land	-	3,801	3,530	3,528	2,435	2,414
Buildings	-	10,373	12,487	10,460	5,863	5,750
Machinery	-	24,513	21,504	17,352	13,921	11,846
Construction In Progress	-	3,061	2,071	4,932	6,699	3,716
Leasehold Improvements	-	101.9	88.8	88.74	64.47	60.1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.